Cheapest GLP-1 without insurance 2026: Ozempic, Wegovy, Mounjaro & Zepbound prices compared

The cheapest GLP-1 without insurance in 2026 is compounded semaglutide at roughly $149–$300 per month through online telehealth providers or through canadian pharmacies.

For FDA-approved brand-name options, Wegovy injectable starts at $199 per month for new self-pay patients through NovoCare, while Zepbound begins at $299 per month through LillyDirect. These prices represent a dramatic shift from the $1,000+ list prices that defined GLP-1 medications just two years ago.

In case you are not able to afford these medications then you can make use of the Canadian pharmacies and prescription referral services that provide these drugs at very low cost. This means Ozempic for $379.99, Wegovy for $599.99, and Zepbound for $499.99.

The result has been an explosion in demand, with roughly 40 million Americans having tried a GLP-1 for weight loss, according to a 2026 RAND report. The problem is paying for them, especially if your insurance provider denies coverage or you have no insurance at all.

TL;DR

• Brand-name GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound carry list prices between $998 and $1,349 per month without insurance. 
• Almost nobody should pay that. In 2026, manufacturer cash-pay programs from Novo Nordisk and Eli Lilly have slashed self-pay costs to $199–$449 per month depending on the drug and dose. 
• Compounded semaglutide from licensed compounding pharmacies runs $149–$400 per month, though these are not FDA approved. 
• Pharmacy discount cards from GoodRx and SingleCare cut another 10–25% off retail for brand-name drugs. 
• Patient assistance programs can bring costs to zero for qualifying low-income patients. 
• And for those open to buying internationally, prescription referral services like Pandameds.com can provide the same medications at 60 to 80% lower prices than U.S. retail.

What GLP-1 medications are FDA approved for weight loss?

The FDA has approved a handful of GLP-1 and dual GIP/GLP-1 medications for chronic weight management. Knowing which drugs carry the weight-loss indication matters because it affects insurance coverage, manufacturer savings card eligibility, and which treatment plan your healthcare provider can prescribe.

Wegovy (semaglutide) 

It was the first weekly injectable GLP-1 approved specifically for weight management in adults with a body mass index of 30 or higher, or 27 and above with at least one weight-related condition such as high blood pressure or type 2 diabetes. In clinical trials, patients on semaglutide 2.4 mg lost an average of about 15% of their body weight over 68 weeks. Novo Nordisk also launched an oral tablet form of Wegovy in 2025, making it the first oral GLP-1 approved for weight loss.

You can learn more about Wegovy dosing and how it works on our dosing guide.

Zepbound (tirzepatide)

It is made by Eli Lilly, is a dual GIP/GLP-1 receptor agonist approved for weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. Tirzepatide targets two gut hormones rather than one, and the clinical trial data reflects that difference. Patients taking the 15 mg dose lost an average of roughly 21% of their body weight over 72 weeks. Zepbound is only available as an injection. 

For a detailed breakdown of Zepbound costs and coverage options, see our dedicated cost guide.

Saxenda (liraglutide) 

It’s an older daily injectable GLP-1 approved for weight management. Average weight loss is more modest, around 5–8% of body weight. A generic version of liraglutide received FDA approval recently and is available for as low as $221 per month with discount coupons, making it the cheapest FDA-approved brand-name GLP-1 injection on the market.

Ozempic (semaglutide) and Mounjaro (tirzepatide) 

These are FDA approved for type 2 diabetes, not for weight loss. Many patients and providers use them off-label for weight management, but this off-label status means insurance coverage for weight loss is harder to obtain, and manufacturer savings cards may not apply unless you have a diabetes diagnosis. 

For a comparison of these medications, check our GLP-1 receptor agonists list.

GLP-1 retail prices without insurance in 2026

Before we get into savings programs and discount strategies, here is what GLP-1 medications actually cost at full retail. These are the list prices, sometimes called Wholesale Acquisition Cost or WAC, that you would pay at a pharmacy counter with no insurance and no discount card. Pharmacies typically add a markup of 10–40% on top of WAC, which is why the same drug can cost different amounts at different pharmacies.

At full retail, the annual cost for an uninsured patient ranges from roughly $10,800 to $16,188 depending on the medication. These numbers explain why so many patients either give up on treatment or turn to compounded alternatives and discount programs.

But if you get these medications from a Canadian pharmacy or a prescription referral service then it will cost you just half the money. 

Manufacturer cash-pay programs and savings cards

Both Novo Nordisk and Eli Lilly now offer direct-to-consumer pricing that bypasses insurance entirely. These cash-pay models were designed for patients whose insurance denies coverage or who have no insurance at all.

NovoCare self-pay (Wegovy)

New self-pay patients who have not filled a Wegovy prescription in the past 365 days can pay $199 per month for the first two fills of Wegovy injectable (0.25 mg and 0.5 mg starter doses). After that, the monthly cost for injections is $349. For the oral Wegovy tablet, the starting doses (1.5 mg and 4 mg) are available at $149 per month through August 2026, with the 4 mg dose rising to $199 per month after that date. Higher doses (9 mg and 25 mg) cost $299 per month. 

You can learn more about how much Wegovy costs in our pricing guide.

LillyDirect self-pay (Zepbound)

Eli Lilly sells Zepbound directly to patients through its LillyDirect platform. The starting dose (2.5 mg) is $299 per month and the 5 mg dose is $399. All higher doses (7.5 mg through 15 mg) are $449 per month through the Zepbound Self Pay Journey Program, provided you refill within 45 days of your previous delivery. Miss that window and prices jump to $599–$1,049 depending on dose. LillyDirect ships to your home or offers pickup at participating Walmart pharmacy locations.

Manufacturer savings cards for insured patients

If you have commercial insurance, manufacturer savings cards can reduce your monthly cost to as low as $25. The Wegovy Savings Card, Ozempic Savings Card, Mounjaro Savings Card, and Zepbound Savings Card all offer this level of savings for eligible patients with private insurance that covers the medication. The savings are subject to monthly and annual caps. Patients on Medicare, Medicaid, or other government insurance programs are excluded from these savings card programs.

Pharmacy discount programs

Pharmacy discount cards from services like GoodRx and SingleCare can provide savings of 10–80% on GLP-1 medications, depending on the drug, dose, and pharmacy. Unlike manufacturer savings cards, these programs have no insurance or income eligibility requirements. Anyone can use them.

GoodRx currently runs an introductory semaglutide program: $199 per month for the first two fills of Ozempic or Wegovy injectable, or $149 for the Wegovy pill at certain doses. After the introductory period, ongoing fills run $299–$349 per month. Zepbound KwikPens are available through GoodRx starting at $299 per month. Foundayo (orforglipron), Eli Lilly’s new daily oral GLP-1, starts at $149 per month through GoodRx.

The biggest savings from discount cards tend to apply at warehouse pharmacies like Costco, Sam’s Club, and HEB, where baseline pricing is already lower. Stack a discount card with pharmacy shopping and you can cut medication costs by hundreds of dollars per year compared to a standard retail pharmacy.

Patient assistance programs for eligible patients

If your household income falls below certain thresholds, you may qualify for free medication through a Patient Assistance Program (PAP). Novo Nordisk’s PAP covers Ozempic and Wegovy for patients with household income at or below 200% of the federal poverty level (roughly $30,120 for a single person in 2026). Eli Lilly’s Lilly Cares program covers Mounjaro and Zepbound for patients at or below 300% of the federal poverty level.

These programs typically require proof of a Medicaid denial letter, documentation of household income, and a prescription from a licensed provider. The application process takes two to four weeks. If you qualify, the medication ships to your medical provider or preferred pharmacy at no cost.

International prescription referral services

For patients who want these medications at prices well below U.S. retail, international prescription referral services offer another path. Services like Pandameds.com connect patients with licensed pharmacies in countries like Canada where the same prescription medications from the same manufacturers cost 60 to 80% less than in the United States. You still need a valid prescription, and the drugs must be for personal use.

This option is particularly relevant for patients on stable maintenance doses who want to save money on brand-name medications rather than using unsafe compounded alternatives. .

GLP-1 medications are meant for long-term use. Stopping abruptly can lead to weight regain. Work with your medical provider on a treatment plan that accounts for your weight loss journey over months and years, not weeks. The FDA’s medication guide for GLP-1 drugs provides full safety information.